Key Findings:  CBD, CBG and THCV may have clinical value in reducing cytokine secretion in lung epithelial cell however, an extract of a cannabis chemotype III (abundant in CBD) containing various terpenes increased pro-inflammatory cytokine production. As such the authors posit that, that for now, cannabinoid-based therapeutics ought to be avoided in the treatment or prevention of COVID-19.
Type of Study:  Laboratory Study
Study Result:  Inconclusive
Study Location(s):  Israel
Year of Pub:  2021
Cannabinoids Studied:  Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source:  Cannabis Flower derived
Chemotype:  Chemotype III